With the closing announced on Sunday of its $275 million purchase of Novartis' flu vaccine business, Australia's CSL is slated to become the world's second-largest flu vaccine supplier. It said on Friday that it secured the necessary approvals for the acquisition and worked through Sunday to finalize the deal.
Early signs of the upcoming flu season came this week as three vaccine makers--GlaxoSmithKline, Sanofi Pasteur and bioCSL--announced their first shipments of flu shots for the 2015-16 season, with two reporting that they will increase the amount of doses they deliver.
Australia's CSL unveiled Phase III trial results for hemophilia B candidate rIX-FP that met the primary endpoint and separately noted it bought exclusive rights to commercialize flu treatment Rapivab from BioCryst Pharmaceuticals last week. The note highlighted the growing reach of the biopharma in a core blood products business and in vaccines following its purchase of a Novartis unit last year.